Total Payments
$1.7M
2024 Payments
$274,194
Companies
38
Transactions
1,850
Medicare Patients
4,457
Medicare Billing
$334,031
Payment Breakdown by Category
Other$1.2M (69.1%)
Consulting$321,873 (18.8%)
Travel$157,943 (9.2%)
Food & Beverage$37,470 (2.2%)
Research$11,559 (0.7%)
Education$645.45 (0.0%)
Gifts$40.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 316 | 61.1% |
| Consulting Fee | $321,873 | 82 | 18.8% |
| Travel and Lodging | $157,943 | 441 | 9.2% |
| Honoraria | $136,734 | 54 | 8.0% |
| Food and Beverage | $37,470 | 892 | 2.2% |
| Unspecified | $11,559 | 26 | 0.7% |
| Education | $645.45 | 38 | 0.0% |
| Gift | $40.59 | 1 | 0.0% |
Payments by Type
General
$1.7M
1,824 transactions
Research
$11,559
21 transactions
Ownership
$0
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $424,403 | 408 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $264,813 | 139 | $0 (2024) |
| Horizon Therapeutics plc | $253,285 | 293 | $0 (2023) |
| Amgen Inc. | $147,848 | 146 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $94,958 | 163 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $91,573 | 91 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $83,200 | 26 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $64,135 | 72 | $0 (2023) |
| Merck Sharp & Dohme LLC | $49,034 | 27 | $0 (2022) |
| F. Hoffmann-La Roche AG | $35,486 | 25 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $274,194 | 271 | Amgen Inc. ($147,848) |
| 2023 | $191,544 | 222 | Horizon Therapeutics plc ($116,057) |
| 2022 | $237,119 | 304 | Horizon Therapeutics plc ($78,392) |
| 2021 | $207,747 | 189 | Mallinckrodt Hospital Products Inc. ($53,873) |
| 2020 | $138,614 | 113 | Biogen, Inc. ($68,618) |
| 2019 | $268,917 | 275 | Mallinckrodt Enterprises LLC ($70,768) |
| 2018 | $211,623 | 209 | Biogen, Inc. ($119,579) |
| 2017 | $182,279 | 267 | Biogen, Inc. ($72,764) |
All Payment Transactions
1,850 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $145.26 | General |
| 12/16/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $44.49 | General |
| 12/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/06/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $25.21 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $126.68 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/02/2024 | ARGENX US, INC. | VYVGART (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Immunology | ||||||
| 12/02/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $47.53 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: Neurology | ||||||
| 11/27/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $11,814.00 | General |
| 11/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $12,565.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,385.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,385.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,590.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $124.52 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| 11/18/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| 11/18/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.37 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $677.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $428.37 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $147.56 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $117.58 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $39.86 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $1,435.88 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $619.96 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $104.63 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) | Alexion Pharmaceuticals, Inc. | $7,200 | 2 |
| EFFICACY AND SAFETY STUDY AS ADD-ON THERAPY OF SATRALIZUMAB SA237 TO TREAT NMO AND NMOSD, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NMO SPECTRUM DISORDER NMOSD | F. Hoffmann-La Roche AG | $2,008 | 7 |
| A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) | Alexion Pharmaceuticals, Inc. | $1,200 | 1 |
| MS700568-0078 | EMD Serono, Inc. | $614.10 | 9 |
| SAKURABONSAI A PROSPECTIVE, OPEN-LABEL STUDY OF SATRALIZUMAB INVESTIGATING NOVEL IMAGING, BIOMARKER, AND CLINICAL OUTCOMES IN PATIENTS WITH AQUAPORIN-4-IGG-SEROPOSITIVE AQP4-IGG NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | F. Hoffmann-La Roche AG | $536.34 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,141 | 1,248 | $186,545 | $86,352 |
| 2022 | 12 | 1,096 | 1,234 | $182,226 | $82,021 |
| 2021 | 11 | 1,137 | 1,268 | $185,584 | $87,561 |
| 2020 | 14 | 1,083 | 1,321 | $188,315 | $78,097 |
Total Patients
4,457
Total Services
5,071
Medicare Billing
$334,031
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 181 | 183 | $35,371 | $18,058 | 51.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 125 | 125 | $32,140 | $15,946 | 49.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 130 | 172 | $23,140 | $11,910 | 51.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 58 | 58 | $19,430 | $9,403 | 48.4% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 151 | 163 | $17,243 | $8,347 | 48.4% |
| 92060 | Exam to measure eye deviation and range of motion | Office | 2023 | 83 | 101 | $10,101 | $5,140 | 50.9% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Facility | 2023 | 157 | 160 | $20,000 | $5,131 | 25.7% |
| 92133 | Imaging of optic nerve | Office | 2023 | 151 | 164 | $10,793 | $4,104 | 38.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 27 | $6,480 | $3,669 | 56.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 30 | $5,204 | $3,000 | 57.6% |
| 93888 | Ultrasound of within the brain blood flow | Facility | 2023 | 12 | 28 | $2,800 | $588.00 | 21.0% |
| 93886 | Complete ultrasound of within the brain blood flow | Facility | 2023 | 11 | 12 | $1,800 | $455.16 | 25.3% |
| 92134 | Imaging of retina | Office | 2023 | 14 | 14 | $944.00 | $377.08 | 39.9% |
| 93882 | Ultrasound of one side of head and neck blood flow | Facility | 2023 | 11 | 11 | $1,100 | $222.64 | 20.2% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 153 | 154 | $29,962 | $14,246 | 47.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 110 | 110 | $28,227 | $13,546 | 48.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 122 | 168 | $22,824 | $11,816 | 51.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 66 | 66 | $21,920 | $11,602 | 52.9% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 129 | 142 | $14,961 | $7,045 | 47.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Facility | 2022 | 189 | 200 | $25,000 | $6,467 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 31 | $7,440 | $4,068 | 54.7% |
| 92060 | Exam to measure eye deviation and range of motion | Office | 2022 | 74 | 79 | $7,914 | $3,909 | 49.4% |
| 92133 | Imaging of optic nerve | Office | 2022 | 139 | 146 | $9,238 | $3,897 | 42.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 31 | $5,402 | $3,097 | 57.3% |
| 93888 | Ultrasound of within the brain blood flow | Facility | 2022 | 12 | 65 | $6,500 | $1,389 | 21.4% |
About Dr. Robert Sergott, MD
Dr. Robert Sergott, MD is a Ophthalmology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1285634105.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Sergott, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $274,194 received in 2024. These payments were reported across 1,850 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Sergott has provided services to 4,457 Medicare beneficiaries, totaling 5,071 services with total Medicare billing of $334,031. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Neuro-ophthalmology
- Location Philadelphia, PA
- Active Since 07/21/2005
- Last Updated 07/21/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1285634105
Products in Payments
- ACTHAR (Biological) $356,386
- UPLIZNA (Drug) $184,646
- TECFIDERA (Drug) $170,817
- UPLIZNA (Biological) $127,013
- VUMERITY (Drug) $105,227
- TEPEZZA (Drug) $65,674
- SOLIRIS (Drug) $59,800
- ZEPOSIA (Drug) $44,920
- TYSABRI (Biological) $34,219
- MK-8931 (Drug) $29,434
- Ponvory (Drug) $28,431
- VYVGART (Drug) $24,934
- AUBAGIO (Drug) $22,951
- Mavenclad (Biological) $21,145
- MAYZENT (Drug) $20,109
- OCREVUS (Biological) $17,167
- Enspryng (Biological) $15,834
- PLEGRIDY (Biological) $11,575
- TEPEZZA (Biological) $11,434
- GILENYA (Drug) $11,190
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Philadelphia
Mark Blecher, Md, MD
Ophthalmology — Payments: $591,672
Ophthalmology $591,672
Dr. Joshua Greene, Md, MD
Ophthalmology — Payments: $488,392
Ophthalmology $488,392
Joseph Markoff, Md Phd, MD PHD
Ophthalmology — Payments: $441,634
Ophthalmology $441,634
Dr. Jonathan Myers, M.d, M.D
Ophthalmology — Payments: $412,982
Ophthalmology $412,982
Beeran Meghpara, M.d, M.D
Ophthalmology — Payments: $330,295
Ophthalmology $330,295
Dr. Leslie Katz, M.d, M.D
Ophthalmology — Payments: $220,542
Ophthalmology $220,542